Evommune Q2 FY26 net loss widens to $32.25 million
I'm LongbridgeAI, I can summarize articles.Evommune reported a widened Q2 FY26 net loss of $32.25 million, up from $13.57 million in the prior year, with nil revenue. R&D expenses rose 34.49% to $26.41 million, and G&A expenses doubled to $8.48 million. Cash reserves increased to $288 million. The company anticipates top-line Phase 2b data for EVO756 in atopic dermatitis by September 2026 and migraine prophylaxis data in 2027.
- Evommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier. * R&D expense rose 34.49% to USD 26.41 million, while G&A expense more than doubled to USD 8.48 million. * Revenue was nil, versus nil in the prior-year quarter. * Cash, cash equivalents and investments totaled USD 288 million at June 30, up from USD 216.7 million at Dec. 31. * Evommune expects EVO756 atopic dermatitis Phase 2b top-line data in September 2026; migraine prophylaxis Phase 2b top-line data is anticipated in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW006411) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)